Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SporeVax Tetanus
- Development stage
- Preclinical
- Lead developer
- SporeGen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral, Intranasal
01
Overview
SporeVax Tetanus is a preclinical spore-based mucosal vaccine candidate being developed by SporeGen (Spobiotic Research Center) for the prevention of tetanus. The vaccine utilizes *Bacillus subtilis* spores as a delivery platform for mucosal administration via oral or nasal routes. This approach is designed to elicit protective immunity against *Clostridium tetani* by stimulating both systemic and mucosal immune responses. The technology leverages the inherent stability and adjuvant properties of bacterial spores to potentially eliminate the need for cold-chain storage and needle-based administration, offering a more accessible vaccination method.
- Brand names
- SporeVax Tetanus
- Other names
- SporeVax + tetanusSporeGen spore-based mucosal vaccineSporeVax-Tetanus vaccine
02
Targets
TTC (Tetanus neurotoxin heavy chain fragment C)
Beyond the preview
Go deeper on SporeVax Tetanus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SporeVax Tetanus.